A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis
A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis
This is a multi-center, randomized, double-blind, active-controlled, non-inferiority, phase 3
 study to evaluate the efficacy and safety of MCT-SR in patients with gastritis.
To contribute greater treatment compliance and patient convenience, the rebamipide SR
 formulation has been developed.
Inclusion Criteria:

 -  Adult males and females aged ≥19 and <75 years

 -  Patients diagnosed with acute or chronic gastritis by gastroscopy with at least 1
 erosion confirmed by gastroscopy within 7 days prior to the first dose of the
 Investigational Product(IP)

 Exclusion Criteria:

 -  Patients ineligible for gastroscopy

 -  Patients who took other drugs for treating gastritis within 2 weeks prior to the first
 dose of the IP.

 -  Patients who have to continue taking drugs that may induce gastritis

 -  Other clinically significant medical or psychiatric findings that the investigator
 considers inappropriate for the study